Abstract
Background: Cardiovascular diseases, especially ischemic heart disease and cardiometabolic disease, remain to be the leading cause of morbidity and mortality worldwide. Despite recent progress in diagnostic and therapeutic approaches, the incidence of cardiovascular disease is still rising. Therefore, alternative favorable treatment is urgently needed to rescue the fast growing numbers of patients.
Objective: Herein we aimed to review the relevant role and explore the possibility of SIRT1 as a promising target for protection of heart from ischemia/reperfusion injury and cardiometabolic diseases.
Results: The activation of SIRT1 participates in a variety of important metabolic and physiologic processes including stress resistance, metabolism, apoptosis and energy balance in heart ischemia injury and cardiometabolic disease.
Conclusion: Current medication targeting SIRT1 may represent a new therapeutic trend for the prevention of cardiovascular disease that is related to energy balance and metabolism.
Keywords: SIRT1, ischemia reperfusion injury, metabolic disease, heart, resveratrol, therapy, target.
Current Drug Targets
Title:SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Volume: 18 Issue: 15
Author(s): Dong Han, Jinda Wang, Sai Ma, Yundai Chen and Feng Cao*
Affiliation:
- Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853,China
Keywords: SIRT1, ischemia reperfusion injury, metabolic disease, heart, resveratrol, therapy, target.
Abstract: Background: Cardiovascular diseases, especially ischemic heart disease and cardiometabolic disease, remain to be the leading cause of morbidity and mortality worldwide. Despite recent progress in diagnostic and therapeutic approaches, the incidence of cardiovascular disease is still rising. Therefore, alternative favorable treatment is urgently needed to rescue the fast growing numbers of patients.
Objective: Herein we aimed to review the relevant role and explore the possibility of SIRT1 as a promising target for protection of heart from ischemia/reperfusion injury and cardiometabolic diseases.
Results: The activation of SIRT1 participates in a variety of important metabolic and physiologic processes including stress resistance, metabolism, apoptosis and energy balance in heart ischemia injury and cardiometabolic disease.
Conclusion: Current medication targeting SIRT1 may represent a new therapeutic trend for the prevention of cardiovascular disease that is related to energy balance and metabolism.
Export Options
About this article
Cite this article as:
Han Dong, Wang Jinda, Ma Sai, Chen Yundai and Cao Feng*, SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450116666150630110529
DOI https://dx.doi.org/10.2174/1389450116666150630110529 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Current Cardiology Reviews Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Current Neuropharmacology Pharmacogenetics and Statin Treatment: Reality or Theory?
Current Vascular Pharmacology Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC
Current Stem Cell Research & Therapy Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology The Start of a New Era for Stroke Treatment: Mechanical Thrombectomy Devices
Current Neurovascular Research Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design